Published in Drug Week, March 31st, 2006
According to recent research from Poland, "The tetrapeptide (AcSDKP), a physiologic inhibitor of stem-cell proliferation, is also known for its strong angiogenic activity. It has been shown that blood levels of this peptide are increased in some hematological malignancies."
"However, no data on the concentration of AcSDKP present in solid tumor tissue are available. The aim of our study was to measure tissue concentration of AcSDKP in benign and malignant lesions of the thyroid gland," wrote M. Kusinski and colleagues, Medical University of Lodz.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week